Employees: 11 (2023.0)Legal category: 5785Size: PMECreation date: 2001-02-01 (25 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: CLEON-D'ANDRAN (26450), Drome
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE CENTRALE DE LA VALDAINE : revenue, balance sheet and financial ratios
PHARMACIE CENTRALE DE LA VALDAINE is a French company
founded 25 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in CLEON-D'ANDRAN (26450),
this company of category PME
shows in 2025 a net income positive of 422 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE CENTRALE DE LA VALDAINE (SIREN 438800641)
Indicator
2025
2024
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
421 905 €
424 267 €
811 254 €
513 536 €
416 271 €
362 970 €
411 932 €
401 727 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE CENTRALE DE LA VALDAINE generates positive net income of 422 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 402 k€ -> 422 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
421 905 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 68%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 48%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
68.0%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
47.584%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE CENTRALE DE LA VALDAINE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2024
2025
Debt ratio
82.976
70.248
114.298
63.912
41.106
32.527
28.33
68.0
Financial autonomy
46.602
49.509
40.08
49.78
59.025
63.022
61.394
47.584
Repayment capacity
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
68.02025
2022
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average+27 pts over 3 years
In 2025, the debt ratio of PHARMACIE CENTRALE DE LA ... (68.00) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
47.58%2025
2022
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average-28 pts over 3 years
In 2025, the financial autonomy of PHARMACIE CENTRALE DE LA ... (47.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 180.02. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
180.022
Liquidity indicators evolution PHARMACIE CENTRALE DE LA VALDAINE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2024
2025
Liquidity ratio
238.831
230.778
274.38
184.776
205.431
277.823
186.079
180.022
Interest coverage
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
180.022025
2022
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average-26 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE CENTRALE DE LA ... (180.02) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Positioning of PHARMACIE CENTRALE DE LA VALDAINE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE CENTRALE DE LA VALDAINE is estimated at
6 702 011 €
(range 4 548 016€ - 10 516 378€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
4548k€6702k€10516k€
6 702 011 €Range: 4 548 016€ - 10 516 378€
NAF 5 année 2025
Valuation method used
Net Income Multiple
421 905 €
×
15.9x
=6 702 011 €
Range: 4 548 016€ - 10 516 378€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE CENTRALE DE LA VALDAINE with other companies in the same sector:
Frequently asked questions about PHARMACIE CENTRALE DE LA VALDAINE
What is the revenue of PHARMACIE CENTRALE DE LA VALDAINE ?
The revenue of PHARMACIE CENTRALE DE LA VALDAINE is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE CENTRALE DE LA VALDAINE profitable?
Yes, PHARMACIE CENTRALE DE LA VALDAINE generated a net profit of 422 k€ in 2025.
Where is the headquarters of PHARMACIE CENTRALE DE LA VALDAINE ?
The headquarters of PHARMACIE CENTRALE DE LA VALDAINE is located in CLEON-D'ANDRAN (26450), in the department Drome.
Where to find the tax return of PHARMACIE CENTRALE DE LA VALDAINE ?
The tax return of PHARMACIE CENTRALE DE LA VALDAINE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE CENTRALE DE LA VALDAINE operate?
PHARMACIE CENTRALE DE LA VALDAINE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart